Isis Pharmaceuticals News
The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.
Exelixis, Cell Therapeutics, Isis Pharmaceuticals, and Amarin could make health care headlines this morning. Here's why.
A trio of positive clinical trials, a newly approved indication for a well-known cancer drug, and an up-and-coming biotech juggernaut ringing the register on another milestone payment, are this week's top biotech stories.
The year started with a bang for Isis Pharmaceuticals with the first antisense treatment approved by the FDA in nearly 15 years. But since then, things have gone quiet -- but its stock is still climbing -- are investors right to buy?
Stocks with insider trader activity include AHL, CNQR, CHE, ISIS and MNST
Isis Pharmaceuticals continues to progress well with its collaboration agreement with GlaxoSmithKline, which is focused on the discovery and development of new therapeutics against targets for rare and/or serious diseases.
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a new lifetime high candidate
Isis Pharmaceuticals was a winner within the drugs industry, rising $1.59 (4.3%) to $38.14 on average volume
Teva is losing patent protection on its multi billion cancer drug Copaxone in 2015 and that has the company increasingly reliant on its pipeline. The company expects Phase 3 data early next year for Custirsen, a prostate drug it hopes will offset some of Copaxone's expected sales drop.
John Kastelein The triglycerides that are mostly associated with coronary artery disease and severely high elevated levels of triglycerides which are associated with other conditions such as pancreatitis ...
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a "dead cat bounce" (down big yesterday but up big today) candidate